| Tamara L Ender, LMFT LCSW | |
|
212 S 11th Street, Lacrosse, WI 54601 | |
| (608) 791-9555 | |
| (608) 791-9432 |
| Full Name | Tamara L Ender |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 212 S 11th Street, Lacrosse, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215975016 | NPI | - | NPPES |
| 39788900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 4232 (Wisconsin) | Primary |
| 106H00000X | Marriage & Family Therapist | 486 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tamara L Ender, LMFT LCSW 700 West Avenue South, Attn Physician Services, Lacrosse, WI 54601 Ph: (608) 791-4156 | Tamara L Ender, LMFT LCSW 212 S 11th Street, Lacrosse, WI 54601 Ph: (608) 791-9555 |
News Archive
The ongoing wars in Iraq and Afghanistan have resulted in uniquely destructive patterns of combat injuries, including limb-threatening injuries to the knee. In the March special issue of Techniques in Knee Surgery military surgeons serving in Operation Iraqi Freedom and Operation Enduring Freedom share their experience with managing these high-energy injuries of the knee. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
Mercury, the main ingredient in "silver" or amalgam fillings, will be the subject of a United Nations conference to be held in Chiba, Japan on January 24-28. Members of various non-governmental organizations, as well as dentists and scientists from groups such as the International Academy of Oral Medicine and Toxicology, will be attending and urging a ban on products containing mercury, including dental amalgam.
ConversePoint, a privately owned company based in Chicago, has announced its plans to develop and commercialize a communications platform for the healthcare industry that will significantly save clinicians time, hospitals millions in productivity costs and improve accountability measurements for critical events per the Joint Commission's National Patient Safety Goals along with the license of key Qualcomm technology.
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation at the Eighth International Kidney Cancer Symposium, to be held in Chicago from September 25-26, 2009.
› Verified 8 days ago